New Products

PARSIPPANY, N.J. — The Food and Drug Administration has approved a generic opioid painkiller made by Actavis, the drug maker said.

HAIFA, Israel — Self-reported medication adherence rates increased among Type 2 diabetes patients using a mobile app, the maker of the app said Monday.

MediSafe Project said it reviewed adherence rates among Type 2 diabetic users of its app, finding compliance rates at least 26% higher than the generate rate for long-term diabetes therapies, which the World Health Organization reports as 50%. A January 2013 study of the app, which the company launched in November 2012, found similar rates.

ALEXANDRIA, Va. — The National Community Pharmacists Association on Thursday announced the introduction of a resource kit — Take Charge of Rx Benefits in Your Community — to help preempt anti-patient drug benefit designs, such as those that require the use of mail-order facilities for prescription drugs.

LAS VEGAS — LashDip, a semi-permanent lash enhancement line that uses gel-based coating to make lashes lusher, has launched its first retail line.

It is not a lash extension or a strip; rather it is a weightless, gel-based coating that delivers all the perks of mascara but lasts for weeks.

NEW YORK — Looking to further innovate the at-home gel manicure market, Red Carpet Manicure has developed the first at-home light-activated nail treatments.

The manufacturer behind the diet-aid supplement Hydroxycut, Iovate Health Sciences International, recently introduced two new formats to its popular weight-loss franchise: Pro Clinical Hydroxycut Sprinkles and Pro Clinical Hydroxycut Gummies. The first represents a diet aid that is sprinkled on a diet-friendly food, such as a salad, that helps boost weight loss, and the second capitalizes on another booming trend in the supplement space — adult vitamins in gummy form.

PARSIPPANY, N.J. — Actavis is looking to become the first to market a generic drug for epilepsy, the company said Friday.

Actavis announced that it had filed with the Food and Drug Administration for lacosamide tablets in the 50-mg, 100-mg, 150-mg and 200-mg strengths. The drug is a generic version of UBC's Vimpat and is used to treat partial-onset seizures in epilepsy patients aged 17 and older.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new lung cancer drug made by Boehringer Ingelheim, the agency said Friday.

The FDA announced the approval of Gilotrif (afatinib) for patients with non-small cell lung cancer that has spread to other parts of the body and whose tumors include certain epidermal growth factor receptor gene mutations. The drug works by blocking proteins that promote the development of cancer cells.